Nasdaq · Healthcare

RECURSION PHARMACEUTICALS, INC. (RXRX)

As-reported financials and recent SEC filings for RECURSION PHARMACEUTICALS, INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$74.7M

Net income

$-644.8M

Net margin

—

Diluted EPS

$-1.44

ROE

-57.0%

P/E (TTM)

—

Market cap

—

Debt / equity

0.0×

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$74.7M	$58.8M	$44.6M	$39.8M	$10.2M
Gross profit	$3.7M	$13.6M	$2.0M	$-8.4M	—
Operating income	$-648.1M	$-479.0M	$-350.1M	$-245.7M	$-182.8M
Net income	$-644.8M	$-463.7M	$-328.1M	$-239.5M	$-186.5M
Diluted EPS	$-1.44	$-1.69	$-1.58	$-1.36	$-1.49

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

1442026-07-06

1442026-07-02

42026-07-02

42026-07-02

1442026-07-01

42026-06-22

42026-06-22

42026-06-22

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on RXRX

Search RECURSION PHARMACEUTICALS, INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.